The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
|
|---|---|
| Published in |
Frontiers in Surgery, June 2017
|
| DOI | 10.3389/fsurg.2017.00035 |
| Pubmed ID | |
| Authors |
Harish N. Vasudevan, David R. Raleigh, Julian Johnson, Adam A. Garsa, Philip V. Theodosopoulos, Manish K. Aghi, Christopher Ames, Michael W. McDermott, Igor J. Barani, Steve E. Braunstein |
| Abstract |
To evaluate the efficacy and toxicity of fractionated stereotactic radiotherapy (FSRT) for chordoma and chondrosarcoma. Twenty consecutive patients with a histopathologic diagnosis of chordoma (n = 16) or chondrosarcoma (n = 4) treated between 2010 and 2016 were retrospectively identified. All patients underwent FSRT in five fractions to a median dose of 37.5 Gy (range: 25-40 Gy) and followed with serial magnetic resonance imaging. Overall survival (OS), local recurrence-free survival (LRFS), and event-free survival (EFS) were estimated using the Kaplan-Meier method. With a median follow-up of 28 months after FSRT and 40 months after initial surgery, crude OS and LRFS were 90%. Nine patients (45%) reported grade 1-3 acute toxicity, and two patients (10%) experienced grade 4, 5 late toxicity. One patient previously treated with proton therapy died from radiation vasculopathy 9 months after FSRT. The use of FSRT for recurrent disease or in patients with prior radiation therapy was associated with significantly decreased EFS. FSRT for chordoma and chondrosarcoma is associated with high rates of OS and local control. Although many patients experience acute toxicity, there is a low incidence of late toxicity or irreversible treatment related morbidity despite the frequency of prior radiotherapy in this population. FSRT is an effective adjuvant or salvage treatment for chordoma and chondrosarcoma. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 11% |
| Researcher | 3 | 9% |
| Student > Postgraduate | 3 | 9% |
| Professor > Associate Professor | 3 | 9% |
| Student > Master | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 15 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 40% |
| Engineering | 2 | 6% |
| Neuroscience | 2 | 6% |
| Materials Science | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 15 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2017.
All research outputs
#18,556,449
of 22,982,639 outputs
Outputs from Frontiers in Surgery
#941
of 2,959 outputs
Outputs of similar age
#241,677
of 316,289 outputs
Outputs of similar age from Frontiers in Surgery
#6
of 17 outputs
Altmetric has tracked 22,982,639 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,959 research outputs from this source. They receive a mean Attention Score of 2.3. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,289 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.